ResMed Inc. (RMD) To Go Ex-Dividend on May 14th

ResMed Inc. (NYSE:RMD) announced a quarterly dividend on Thursday, April 30th. Investors of record on Thursday, May 14th will be given a dividend of 0.60 per share by the medical equipment provider on Thursday, June 18th. This represents a c) dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, May 14th.

ResMed has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 13 years. ResMed has a payout ratio of 22.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect ResMed to earn $12.10 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 19.8%.

ResMed Stock Down 4.0%

RMD stock opened at $205.17 on Friday. The company’s 50 day moving average price is $233.35 and its 200 day moving average price is $246.69. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. ResMed has a fifty-two week low of $198.64 and a fifty-two week high of $293.81. The firm has a market capitalization of $29.89 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.41 and a beta of 0.85.

ResMed (NYSE:RMD) last released its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. ResMed had a net margin of 27.44% and a return on equity of 25.72%. The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period in the prior year, the firm earned $2.37 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, equities research analysts anticipate that ResMed will post 11.05 EPS for the current fiscal year.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.